Please ensure Javascript is enabled for purposes of website accessibility

These Secret Ingredients Led Lexicon Pharmaceuticals, Inc. Up 109% in 2015

By Sean Williams - Jan 8, 2016 at 10:02AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Look no further than these two catalysts as to why Lexicon Pharmaceuticals more than doubled in 2015.

LXRX Chart

Shares of Lexicon Pharmaceuticals (LXRX 0.00%), a clinical-stage biopharmaceutical company focused on the development of small-molecule drugs, exploded higher by 109% in 2015, based on data from S&P Capital IQ, thanks to two major catalysts.

The first break for Lexicon Pharmaceuticals came in early August, when it reported positive top-line results for a late-stage study known as TELESTAR for experimental drug telotristat etiprate. Telotristat etiprate is an oral drug designed for patients with carcinoid syndrome that, in clinical trials, showed a statistically significant reduction in bowel movements when added to current standards of care at both the 250 mg and 500 mg dose. The promising results certainly caught Wall Street and investors off guard, and telotristat etiprate looks to become Lexicon's first commercial product, if it's approved by the Food and Drug Administration.

Image source: Centers for Disease Control and Prevention.

Lexicon's second big break came in November, when it announced that its promising type 1 and type 2 diabetes therapy sotagliflozin had found a licensing partner. Under the terms of the announced deal, Sanofi (SNY 1.02%) agreed to pay Lexicon $300 million upfront, removing near-term cash concerns for Lexicon, as well as providing the opportunity to earn an additional $1.4 billion in development, regulatory, and sales milestone payments. Sanofi plans to head the development of sotagliflozin as it pertains to type 2 diabetes (this represents 90%-95% of all diabetes cases), while Lexicon will be responsible for trials pertaining to type 1 diabetes.

What makes sotagliflozin so unique, and the likely reason Sanofi latched on with such a potentially large dangling carrot, is its operating pathway. Sotagliflozin is an SGLT1 and SGLT2 inhibitor. SGLT2 inhibitors like Invokana, Jardiance, and Farxiga have already been approved by the FDA, and they've not only helped improve glycemic balance in type 2 diabetes patients, but they've also induced weight loss and lowered systolic blood pressure for these patients. SGLT2 inhibitors work by blocking glucose absorption in the kidneys and allowing patients to remove excess glucose through their urine. SGLT1 works via the gastrointestinal tract, doing much the same (i.e., inhibiting glucose absorption in order to control a patients' blood sugar level). The combination of SGLT1 and SGLT2 into one drug is intriguing, and it could very well lead to blockbuster status if approved.

What can shareholders look forward to in 2016? The big catalyst looks to be the release of phase 3 data in two out of three type 1 diabetes trials, with the third expected early in 2017. If all goes well, Lexicon could be set for another outstanding performance in 2016.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Lexicon Pharmaceuticals, Inc. Stock Quote
Lexicon Pharmaceuticals, Inc.
$1.73 (0.00%) $0.00
Sanofi Stock Quote
$52.56 (1.02%) $0.53

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.